Agaricus blazei Mushroom: History and Traditional Use

Most famous medicinal mushrooms carry histories measured in centuries. Agaricus blazei — the almond-scented "sun mushroom" of Brazil, the himematsutake of Japan — has a history measured in decades, and that is exactly what makes it interesting. Its story runs from a farming town in the hills of São Paulo state in the 1960s, through a parcel of specimens mailed to Japan, a cultivation breakthrough, a naming dispute that is still not fully settled, one of the biggest health-food booms Japan has ever seen, and a sobering round of safety questions from Japanese regulators. Along the way it acquired a longevity legend of its own — one that, unlike reishi's two-thousand-year-old mythology, was born within living memory and can be examined. This article tells that story as the record actually supports it: where a claim is documented we say so, and where it is folklore, marketing, or unverified legend, we name it as such.

Table of Contents

  1. A Mushroom from the Hills of Piedade
  2. Furumoto's Parcel: From Brazil to Japan
  3. Himematsutake and the Japanese Health-Food Boom
  4. Three Names, One Mushroom: The Taxonomy Dispute
  5. The Forgotten American Chapter: Peck's Almond Mushroom
  6. The Beta-Glucan Research Era in Japan
  7. The 2000s Boom and Japan's Note of Caution
  8. The Norwegian Research Line: AndoSan
  9. What the Evidence Shows Today
  10. Research Papers and References
  11. Connections
  12. Featured Videos

A Mushroom from the Hills of Piedade

The modern story begins in and around Piedade, a rural town in the interior hill country of São Paulo state in southeastern Brazil — a region that, by the mid-twentieth century, was home to a substantial community of Japanese immigrants and their descendants working the land. In the pastures and enriched soils of that warm, humid countryside grew a fleshy white-to-golden mushroom with a firm stem, a distinct almond-like taste and aroma, and a liking for open, sun-exposed ground. Local names recorded for it include cogumelo do sol ("sun mushroom"), cogumelo de Deus ("mushroom of God"), and cogumelo da vida ("mushroom of life") — names that already carry a whiff of the reverence, and of the marketing, that would later surround it.

Wrapped around the mushroom's discovery is a story that deserves honest handling, because it appears in nearly every account and is almost never sourced. The tale holds that the people of the Piedade region ate the sun mushroom as a regular part of their diet, and that they enjoyed conspicuously good health and long lives as a result — in some versions, that visiting researchers were drawn to the area by reports of unusually low rates of serious disease among its inhabitants and traced the effect to the mushroom. It is a compelling story. It is also, on the published record, an epidemiological legend: no formal population study of Piedade substantiating lower disease rates or longer lifespans has ever been published, and careful reviews of the mushroom's literature note that even the extent of genuine local folk consumption before the 1960s is poorly documented. What can be said with confidence is that the mushroom grew there, that it was locally known and eaten at least occasionally, and that the "village of long life" framing spread because it was useful to the health-food industry that came later.

None of that makes the mushroom itself uninteresting — quite the opposite. But it does mean that Agaricus blazei, unlike reishi or maitake, entered the world of medicinal mushrooms without centuries of documented traditional use behind it. Its "tradition" is essentially a single generation deep, and everything that follows in this history happened, remarkably, within about sixty years.

Back to Table of Contents

Furumoto's Parcel: From Brazil to Japan

The person who set the modern story in motion was Takatoshi Furumoto, a grower of Japanese descent farming near Piedade. Furumoto took an interest in the local sun mushroom, and in 1965 he sent specimens and spores to Japan for study. The material reached Inosuke Iwade, founder of the Iwade Research Institute of Mycology in Mie Prefecture — a laboratory devoted to the study and cultivation of useful fungi. This unglamorous act, a farmer mailing a parcel of mushrooms across the Pacific, is the genuine founding event of everything that followed, and it is one of the best-documented facts in the mushroom's early record: the 1965 date and the Furumoto-to-Iwade transfer are repeated consistently across the scientific literature.

Two years later, in 1967, the Belgian mycologist Paul Heinemann examined the Brazilian material and identified it as Agaricus blazei Murrill, a species that had been described from Florida two decades earlier. The identification was reasonable on the evidence of the day, and it stuck: for the next third of a century, virtually every scientific paper, patent, and product label would carry the name Agaricus blazei. As a later section explains, the identification eventually proved to be mistaken — which is why this page, like the main article, must juggle three Latin names for one fungus — but "blazei" had by then been written into so much literature and commerce that it remains the name most people know.

Iwade's institute then did the slow work that turned a wild curiosity into a crop: developing methods to fruit the mushroom reliably indoors and outdoors on prepared compost. Accounts of the effort describe roughly a decade of trial and error before dependable cultivation was achieved in the mid-1970s, and the institute's named cultivars — most famously "Iwade strain 101" — went on to anchor Japanese commercial production and appear by name in later clinical research. Brazil, for its part, developed its own outdoor cultivation industry and became a major exporter of dried fruiting bodies, much of it bound for the Japanese market. The mushroom that had grown half-noticed in Piedade's pastures was now an agricultural commodity on two continents.

Back to Table of Contents

Himematsutake and the Japanese Health-Food Boom

In Japan the newcomer needed a Japanese name, and it received a flattering one: himematsutake (姫マツタケ), usually rendered "princess matsutake." The name borrows the prestige of the matsutake — the wild pine mushroom that is among the most prized foods in Japan — while the "hime" (princess) marks the newcomer's more slender, delicate build. In Japanese mycological writing it also goes by kawariharatake, and in the trade it is often called simply "Agaricus," a genus name pressed into service as a brand. As with reishi and its "ten-thousand-year mushroom" epithet, the names are a small window into how the mushroom was positioned from the start: not as a vegetable, but as something special.

What ignited genuine excitement was laboratory research. In the early 1980s, Japanese university and research-institute groups began reporting at national cancer-research meetings and in journals that polysaccharide fractions from himematsutake fruiting bodies inhibited transplanted tumours in mice. Work associated with Mie University and other Japanese laboratories through the 1980s extended these findings, and the compositional studies of Takashi Mizuno at Shizuoka University — described in the beta-glucan section below — gave them chemical substance. The findings were real, but they were findings in rodents, of the same broad kind already reported for shiitake, maitake, and turkey tail polysaccharides. What happened next was less about the data than about the market.

Through the late 1980s and 1990s, himematsutake became one of the most successful health foods in Japan, promoted heavily — with the Piedade longevity legend doing steady service in the advertising — and adopted above all by cancer patients seeking complementary therapies. Granules, dried mushrooms, teas, and hot-water extracts multiplied; prices for premium products were high; and the mushroom's reputation ran well ahead of any human evidence, which at that point consisted of almost nothing. By the time formal surveys were taken in the 2000s, as described below, Agaricus products had become the single most used complementary medicine among Japanese cancer patients — a remarkable position for a mushroom that had been scientifically unknown forty years earlier.

Back to Table of Contents

Three Names, One Mushroom: The Taxonomy Dispute

Few medicinal mushrooms have a naming tangle as well documented — or as consequential for anyone searching the literature — as this one. The name everyone uses, Agaricus blazei Murrill, was created in 1945 by the American mycologist William Alphonso Murrill for a mushroom collected in Florida, and named after the man who found it, a Mr. Blaze. When Heinemann applied that Florida name to the Brazilian sun mushroom in 1967, the two were assumed to be the same species. From the 1990s onward, as cultivated material became abundant and laboratories examined it closely, doubts grew: the Brazilian-Japanese cultivated mushroom did not match Murrill's Florida fungus in key characters. Specialists began writing the cultivated mushroom's name as "Agaricus blazei sensu Heinemann" — "in Heinemann's sense" — a polite way of saying the name was being used for the wrong species.

In 2002, Solomon Wasser and colleagues concluded that the cultivated mushroom was a distinct species and gave it a new name, Agaricus brasiliensis, honouring its Brazilian origin. The correction was short-lived. In 2005, the American Agaricus specialist Richard Kerrigan published a study in Mycologia bringing mating-compatibility tests and DNA evidence to bear, and reached a conclusion nobody had expected: the celebrated Brazilian mushroom is the same biological species as Agaricus subrufescens Peck, described from the northeastern United States in 1893 — a name that, being far older, takes priority. Kerrigan's work also noted that the name A. brasiliensis was unavailable in any case, because it had already been used in the nineteenth century for a different mushroom, making Wasser's name an illegitimate later homonym.

The practical result is that one mushroom now travels under three names. Agaricus subrufescens is the name most taxonomists accept as correct; Agaricus blazei dominates the medical literature, the supplement market, and common usage; and Agaricus brasiliensis persists in a substantial slice of the research literature, especially from the 2000s. Anyone searching databases for evidence must search all three, and this site's own pages lead with "Agaricus blazei" for findability while acknowledging A. subrufescens as the accepted name. The dispute is more than pedantry: it is a caution built into the mushroom's own name that certainty here has been revised more than once.

Back to Table of Contents

The Forgotten American Chapter: Peck's Almond Mushroom

Kerrigan's 2005 synonymy carried a delightful historical payload: if the Brazilian mushroom is Agaricus subrufescens, then its documented history does not begin in Piedade in the 1960s at all. It begins seventy years earlier, in the United States. Agaricus subrufescens was described in 1893 by Charles Horton Peck, the New York State Botanist, from cultivated material, and in the 1890s and early 1900s it was grown commercially in the northeastern United States as a market mushroom — prized, then as now, for its distinctive almond flavour and fragrance, and sold alongside the button mushroom before fading from cultivation and from memory in the early twentieth century.

This means the "discovery" of the sun mushroom in Brazil was, in a strict sense, a rediscovery: a species American growers had once farmed, lost to commerce for half a century, resurfacing in Brazilian pastures to be noticed again by a farmer with a good eye and a connection to Japan. Whether the Brazilian populations descend from native South American stock, from material moved by human activity, or both, is a question researchers have continued to study; the species as now understood has a broad distribution, with close relatives and populations reported from the Americas and beyond.

The almond mushroom's lost American chapter is a useful corrective to the way medicinal mushrooms are often marketed. The same fungus was, in one century, an ordinary and delicious market vegetable; in the next, a "mushroom of God" credited with a village's longevity. The organism did not change — the story told about it did. Holding both versions in mind is a good habit for reading every claim that follows.

Back to Table of Contents

The Beta-Glucan Research Era in Japan

The scientific substance behind the Japanese boom was built largely in the 1980s and 1990s, and the central figure of its compositional chemistry was Takashi Mizuno of Shizuoka University. In work published in 1990 within his long-running "host-mediated antitumor polysaccharides" series, Mizuno and colleagues isolated water-soluble polysaccharides from himematsutake fruiting bodies and demonstrated antitumour activity in the standard mouse models of the day, alongside detailed characterisation of the fractions. His 1995 review in Food Reviews International gathered the chemistry, cultivation, and pharmacology of "kawariharatake" for an international audience, and remains a snapshot of what was actually known at the boom's height.

Chemically, the mushroom proved genuinely interesting. Its fruiting bodies are rich in beta-glucans — the immune-active polysaccharides common to medicinal mushrooms — but with an unusual emphasis: Agaricus blazei is repeatedly reported to carry abundant β-(1→6)-linked glucans and glucan-protein complexes, where many other medicinal species are dominated by β-(1→3) backbones. Japanese groups, including researchers at Mie University working with the cultivated Iwade material, showed these fractions could activate macrophages, natural killer cells, and other arms of innate immunity in laboratory and animal systems, and could inhibit implanted tumours in mice through what Mizuno's school called host-mediated — that is, immune-mediated — mechanisms rather than direct cell killing.

It is worth stating plainly what this era did and did not establish. It established that the mushroom contains characteristic immunologically active polysaccharides, defined their chemistry, and showed reproducible effects in animals — solid, real science. It did not test whether eating the mushroom or its extracts helps human beings with any disease; human trials were essentially absent from this period. The gap between those two things — filled enthusiastically by marketing — is where the next chapter's troubles grew.

Back to Table of Contents

The 2000s Boom and Japan's Note of Caution

By the early 2000s the mushroom was a global commodity: cultivated at scale in Brazil, Japan, and increasingly China — where it is known as ji song rong and which became a dominant producer — and sold worldwide as capsules, granules, teas, and extracts. The scale of its use in Japan was documented in 2005, when Hyodo and colleagues published a nationwide survey of complementary and alternative medicine among Japanese cancer patients in the Journal of Clinical Oncology: among patients using any complementary product, Agaricus preparations were the single most used item, reported by roughly six in ten CAM users — ahead of every other supplement in the country. For a fungus unknown to science in 1960, it was an extraordinary position.

The same period produced the mushroom's most serious moment of scrutiny, and honesty requires telling it in full. In 2006, physicians at a Japanese cancer centre (Mukai and colleagues, Japanese Journal of Clinical Oncology) reported three cancer patients who developed severe hepatic dysfunction — liver damage — while taking Agaricus blazei extracts, judging that the mushroom preparations may have been responsible; the patients included individuals on concurrent cancer therapy, and case reports of this kind cannot prove causation, but the authors considered the association strong enough to warn the oncology community. In the same year, Japan's Food Safety Commission evaluated three commercial Agaricus products after government-commissioned animal testing: one product promoted carcinogenesis in a standard two-stage rat model, and its manufacturer was asked to halt sales, while the other two products tested did not show the effect. Regulators also noted the mushroom's content of agaritine — a hydrazine-family compound found across the genus Agaricus, including the common button mushroom — whose real-world dietary significance remains debated in toxicology.

The 2006 episode did not end Agaricus commerce, in Japan or anywhere else, and it should not be overread: the carcinogenesis finding attached to one specific product, and the hepatotoxicity reports number a handful of cases against enormous consumption. But it permanently changed the mushroom's framing. From then on, responsible reviews — notably Firenzuoli and colleagues' 2008 assessment, which walks through both the Piedade legend and the toxicological record — have treated Agaricus blazei as a promising immunologically active food with open safety questions, particularly for people with liver disease and for cancer patients combining it with hepatically demanding chemotherapy. That dual framing, praise and caution in the same breath, is the honest legacy of the boom years.

Back to Table of Contents

The Norwegian Research Line: AndoSan

The most sustained clinical research programme on the mushroom outside Japan arose, improbably, in Norway. From the mid-2000s, a group centred at Oslo hospitals and laboratories — with the immunologist Geir Hetland and the surgeon-researcher Egil Johnson among its central figures — began studying a commercial Japanese-formulated extract called AndoSan: a water extract based predominantly on Agaricus blazei (about 82 percent), blended with smaller amounts of Hericium erinaceus (lion's mane) and Grifola frondosa (maitake). The group's 2008 review in the Scandinavian Journal of Immunology set out the case from their own and others' work that the mushroom's extracts modulate innate immunity, with possible relevance to infection, allergy, and cancer.

What distinguishes the Norwegian line is that it proceeded to controlled human trials, small but genuine. In healthy volunteers and patient groups, AndoSan was reported to shift cytokine profiles — in several studies in a broadly anti-inflammatory direction. A 2015 randomized, double-blinded study (Tangen and colleagues) gave AndoSan alongside high-dose chemotherapy and autologous stem-cell transplantation in multiple myeloma patients and reported immunomodulatory effects — changes in immune-cell populations and cytokines — without a design able to test survival benefit. A 2016 randomized, single-blinded, placebo-controlled study (Therkelsen and colleagues) in ulcerative colitis reported improved symptom scores, fatigue, and quality-of-life measures over placebo. The group's 2020 review in Nutrients gathers this preclinical and clinical record in one place.

The fair reading of the AndoSan literature is that it is serious, peer-reviewed, and still preliminary: the trials are small, most endpoints are immunological or patient-reported rather than hard clinical outcomes, several studies come from a single research network with ties to the product's distributor disclosed in the papers, and independent replication at scale has not happened. It is nonetheless a milestone in this history — the point where the sun mushroom's evaluation moved, in part, from mouse models and marketing into registered human trials.

Back to Table of Contents

What the Evidence Shows Today

Six decades after Furumoto's parcel, the evidence picture is easy to summarise honestly. The preclinical record is rich: the mushroom's beta-glucans and related compounds reliably activate innate immune cells through well-described receptor pathways, and they inhibit tumours, infections, and inflammatory processes across many animal models. The human record is thin: a modest collection of small trials — Japanese and Korean studies in cancer patients reporting improved natural-killer-cell activity or quality of life during chemotherapy, small metabolic studies reporting improved insulin resistance in type 2 diabetes, and the Norwegian AndoSan trials described above — almost all short, small, and measuring intermediate endpoints. There are no large phase III trials showing that any Agaricus preparation extends survival, prevents cancer, or cures any disease, and no health authority licenses it to treat anything.

The safety file, likewise, stays open rather than closed: the mushroom is widely eaten without incident, but the Japanese hepatotoxicity reports and the 2006 product-specific carcinogenesis finding mean that liver caution — especially alongside chemotherapy or in pre-existing liver disease — remains the standard advice in serious reviews. Product quality is a real variable too: cultivation substrate, extraction method, and even which of the three Latin names a manufacturer searches when citing evidence all shape what is actually in a bottle. The detailed mechanisms, dosing practice, and study-by-study evidence live in the companion Benefits articles and on the main Agaricus blazei Mushroom page; this history is concerned with how the mushroom got here.

And how it got here is, in the end, the most instructive thing about it. Reishi's history is two thousand years of reverence finally meeting laboratory science; Agaricus blazei's is the mirror image — a mushroom with essentially no ancient tradition that acquired a legend, a market, and a research literature almost overnight. Watching that happen inside a single lifetime, complete with an origin myth, a naming crisis, a boom, and a regulatory reckoning, is a compressed education in how all medicinal-plant reputations are made. The mushroom deserves what its whole short history argues for: genuine curiosity, careful trials, and no mythology.

Back to Table of Contents

Research Papers and References

The papers below anchor the events described in this history: the taxonomic revision, the Japanese compositional and animal work, the usage surveys and safety reports, and the Norwegian clinical line. Author names, titles, and journals are given as plain text; only the stable DOI link is hyperlinked, and each opens in a new tab. Every DOI was verified against the Crossref registry before inclusion.

  1. Kerrigan RW. Agaricus subrufescens, a cultivated edible and medicinal mushroom, and its synonyms. Mycologia. 2005;97(1):12–24. — doi:10.1080/15572536.2006.11832834
  2. Firenzuoli F, Gori L, Lombardo G. The medicinal mushroom Agaricus blazei Murrill: review of literature and pharmaco-toxicological problems. Evidence-Based Complementary and Alternative Medicine. 2008;5(1):3–15. — doi:10.1093/ecam/nem007
  3. Mizuno T, Hagiwara T, Nakamura T, et al. Antitumor activity and some properties of water-soluble polysaccharides from "Himematsutake," the fruiting body of Agaricus blazei Murill (Studies on the host-mediated antitumor polysaccharides, Part XIII). Agricultural and Biological Chemistry. 1990;54(11):2889–2896. — doi:10.1271/bbb1961.54.2889
  4. Mizuno T. Kawariharatake, Agaricus blazei Murill: medicinal and dietary effects. Food Reviews International. 1995;11(1):167–172. — doi:10.1080/87559129509541026
  5. Hyodo I, Amano N, Eguchi K, et al. Nationwide survey on complementary and alternative medicine in cancer patients in Japan. Journal of Clinical Oncology. 2005;23(12):2645–2654. — doi:10.1200/JCO.2005.04.126
  6. Mukai H, Watanabe T, Ando M, Katsumata N. An alternative medicine, Agaricus blazei, may have induced severe hepatic dysfunction in cancer patients. Japanese Journal of Clinical Oncology. 2006;36(12):808–810. — doi:10.1093/jjco/hyl108
  7. Hetland G, Johnson E, Lyberg T, Bernardshaw S, Tryggestad AMA, Grinde B. Effects of the medicinal mushroom Agaricus blazei Murill on immunity, infection and cancer. Scandinavian Journal of Immunology. 2008;68(4):363–370. — doi:10.1111/j.1365-3083.2008.02156.x
  8. Tangen JM, Tierens A, Caers J, et al. Immunomodulatory effects of the Agaricus blazei Murrill-based mushroom extract AndoSan in patients with multiple myeloma undergoing high dose chemotherapy and autologous stem cell transplantation: a randomized, double blinded clinical study. BioMed Research International. 2015;2015:718539. — doi:10.1155/2015/718539
  9. Therkelsen SP, Hetland G, Lyberg T, Lygren I, Johnson E. Effect of a medicinal Agaricus blazei Murill-based mushroom extract, AndoSan, on symptoms, fatigue and quality of life in patients with ulcerative colitis in a randomized single-blinded placebo controlled study. PLOS ONE. 2016;11(3):e0150191. — doi:10.1371/journal.pone.0150191
  10. Hetland G, Tangen JM, Mahmood F, et al. Antitumor, anti-inflammatory and antiallergic effects of Agaricus blazei mushroom extract and the related medicinal basidiomycetes mushrooms, Hericium erinaceus and Grifola frondosa: a review of preclinical and clinical studies. Nutrients. 2020;12(5):1339. — doi:10.3390/nu12051339

Live PubMed Searches

Back to Table of Contents

Connections

Back to Table of Contents